NCT06391918 2026-03-13
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
GenVivo, Inc.
Phase 1 Terminated
GenVivo, Inc.
University of Oklahoma
BeOne Medicines
CytomX Therapeutics
Shanghai Juncell Therapeutics
Instil Bio
Domain Therapeutics SA
National University Hospital, Singapore
OSE Immunotherapeutics
Chengdu Baiyu Pharmaceutical Co., Ltd.
Tomsk National Research Medical Center of the Russian Academy of Sciences